Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 200 articles: HTML format

Single Articles

April 2021
1. BINES J, Clark E, Barton C, Restuccia E, et al
   Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
   Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01323.
   PubMed     Abstract available
   
   
   
2. LUOND F, Tiede S, Christofori G
   Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression.
   Br J Cancer. 2021 Apr 6. pii: 10.1038/s41416-021-01328.
   PubMed     Abstract available
   
   
   March 2021
3. DAVE RV, Kim B, Courtney A, O'Connell R, et al
   Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study.
   Br J Cancer. 2021 Mar 25. pii: 10.1038/s41416-020-01234.
   PubMed     Abstract available
   
   
   
4. RAKHA EA, Miligy IM, Quinn CM, Provenzano E, et al
   Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio >/=2.0, HER2 copy number <4.0 signals/cell) cases.
   Br J Cancer. 2021 Mar 24. pii: 10.1038/s41416-021-01351.
   PubMed     Abstract available
   
   
   
5. KROL I, Schwab FD, Carbone R, Ritter M, et al
   Detection of clustered circulating tumour cells in early breast cancer.
   Br J Cancer. 2021 Mar 24. pii: 10.1038/s41416-021-01327.
   PubMed     Abstract available
   
   
   
6. FARVID MS, Spence ND, Rosner BA, Willett WC, et al
   Post-diagnostic coffee and tea consumption and breast cancer survival.
   Br J Cancer. 2021 Mar 24. pii: 10.1038/s41416-021-01277.
   PubMed     Abstract available
   
   
   
7. GRIS-OLIVER A, Ibrahim YH, Rivas MA, Garcia-Garcia C, et al
   PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
   Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01293.
   PubMed     Abstract available
   
   
   
8. JOBARD E, Dossus L, Baglietto L, Fornili M, et al
   Investigation of circulating metabolites associated with breast cancer risk by untargeted metabolomics: a case-control study nested within the French E3N cohort.
   Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01304.
   PubMed     Abstract available
   
   
   February 2021
9. EVANS DG, Phillips KA, Milne RL, Fruscio R, et al
   Survival from breast cancer in women with a BRCA2 mutation by treatment.
   Br J Cancer. 2021 Feb 18. pii: 10.1038/s41416-020-01164.
   PubMed     Abstract available
   
   
   
10. GIORGI ROSSI P, Lebeau A, Canelo-Aybar C, Saz-Parkinson Z, et al
    Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
    Br J Cancer. 2021 Feb 18. pii: 10.1038/s41416-020-01247.
    PubMed     Abstract available
    
    
    
11. LAAS E, Labrosse J, Hamy AS, Benchimol G, et al
    Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-020-01251.
    PubMed     Abstract available
    
    
    
12. REYES-RUIZ A, Calvillo-Rodriguez KM, Martinez-Torres AC, Rodriguez-Padilla C, et al
    The bovine dialysable leukocyte extract IMMUNEPOTENT CRP induces immunogenic cell death in breast cancer cells leading to long-term antitumour memory.
    Br J Cancer. 2021 Feb 3. pii: 10.1038/s41416-020-01256.
    PubMed     Abstract available
    
    
    
13. VAIDYA JS, Bulsara M, Baum M, Tobias JS, et al
    Single-dose intraoperative radiotherapy during lumpectomy for breast cancer: an innovative patient-centred treatment.
    Br J Cancer. 2021 Feb 2. pii: 10.1038/s41416-020-01233.
    PubMed     Abstract available
    
    
    January 2021
14. CABEL L, Berger F, Cottu P, Loirat D, et al
    Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial.
    Br J Cancer. 2021 Jan 21. pii: 10.1038/s41416-020-01227.
    PubMed     Abstract available
    
    
    
15. BROAD RV, Jones SJ, Teske MC, Wastall LM, et al
    Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy.
    Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01226.
    PubMed     Abstract available
    
    
    December 2020
16. ANEMONE A, Consolino L, Conti L, Irrera P, et al
    Tumour acidosis evaluated in vivo by MRI-CEST pH imaging reveals breast cancer metastatic potential.
    Br J Cancer. 2020 Dec 1. pii: 10.1038/s41416-020-01173.
    PubMed     Abstract available
    
    
    
17. ROLVER MG, Pedersen SF
    Putting Warburg to work: how imaging of tumour acidosis could help predict metastatic potential in breast cancer.
    Br J Cancer. 2020 Dec 1. pii: 10.1038/s41416-020-01171.
    PubMed     Abstract available
    
    
    
18. DUSTIN D, Gu G, Beyer AR, Herzog SK, et al
    RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
    Br J Cancer. 2020 Dec 1. pii: 10.1038/s41416-020-01174.
    PubMed     Abstract available
    
    
    
19. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available
    
    
    November 2020
20. BAILLEUX C, Eberst L, Bachelot T
    Treatment strategies for breast cancer brain metastases.
    Br J Cancer. 2020 Nov 30. pii: 10.1038/s41416-020-01175.
    PubMed     Abstract available
    
    
    
21. GATHANI T, Clayton G, MacInnes E, Horgan K, et al
    The COVID-19 pandemic and impact on breast cancer diagnoses: what happened in England in the first half of 2020.
    Br J Cancer. 2020 Nov 30. pii: 10.1038/s41416-020-01182.
    PubMed     Abstract available
    
    
    
22. RIGGIO AI, Varley KE, Welm AL
    The lingering mysteries of metastatic recurrence in breast cancer.
    Br J Cancer. 2020 Nov 26. pii: 10.1038/s41416-020-01161.
    PubMed     Abstract available
    
    
    
23. DWYER AR, Truong TH, Kerkvliet CP, Paul KV, et al
    Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer.
    Br J Cancer. 2020 Nov 4. pii: 10.1038/s41416-020-01094.
    PubMed     Abstract available
    
    
    
24. TAILOR D, Going CC, Resendez A, Kumar V, et al
    Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer.
    Br J Cancer. 2020 Nov 3. pii: 10.1038/s41416-020-01137.
    PubMed     Abstract available
    
    
    
25. KALAW E, Lim M, Kutasovic JR, Sokolova A, et al
    Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1.
    Br J Cancer. 2020;123:1665-1672.
    PubMed     Abstract available
    
    
    
26. LI YY, Gao LJ, Zhang YX, Liu SJ, et al
    Bisphosphonates and risk of cancers: a systematic review and meta-analysis.
    Br J Cancer. 2020;123:1570-1581.
    PubMed     Abstract available
    
    
    
27. MILIGY IM, Toss MS, Shiino S, Oni G, et al
    The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ.
    Br J Cancer. 2020;123:1513-1520.
    PubMed     Abstract available
    
    
    October 2020
28. MOROTTI M, Zois CE, El-Ansari R, Craze ML, et al
    Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer.
    Br J Cancer. 2020 Oct 8. pii: 10.1038/s41416-020-01113.
    PubMed     Abstract available
    
    
    
29. ZHENG G, Sundquist J, Sundquist K, Ji J, et al
    Association of post-diagnostic use of cholera vaccine with survival outcome in breast cancer patients.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01108.
    PubMed     Abstract available
    
    
    
30. PEDROZA DA, Rajamanickam V, Subramani R, Bencomo A, et al
    Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling.
    Br J Cancer. 2020;123:1326-1335.
    PubMed     Abstract available
    
    
    September 2020
31. OLAFSDOTTIR EJ, Borg A, Jensen MB, Gerdes AM, et al
    Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status.
    Br J Cancer. 2020 Sep 17. pii: 10.1038/s41416-020-01056.
    PubMed     Abstract available
    
    
    
32. HU Y, Xu W, Zeng H, He Z, et al
    OXPHOS-dependent metabolic reprogramming prompts metastatic potential of breast cancer cells under osteogenic differentiation.
    Br J Cancer. 2020 Sep 16. pii: 10.1038/s41416-020-01040.
    PubMed     Abstract available
    
    
    
33. ELSHARAWY KA, Mohammed OJ, Aleskandarany MA, Hyder A, et al
    The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer.
    Br J Cancer. 2020 Sep 1. pii: 10.1038/s41416-020-01045.
    PubMed     Abstract available
    
    
    
34. BEDDOK A, Xu HP, Henry AA, Porte B, et al
    Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature.
    Br J Cancer. 2020;123:905-908.
    PubMed     Abstract available
    
    
    
35. WANG L, Wang Q, Xu P, Fu L, et al
    YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer.
    Br J Cancer. 2020;123:1000-1011.
    PubMed     Abstract available
    
    
    
36. DE MUNCK L, Siesling S, Fracheboud J, den Heeten GJ, et al
    Impact of mammographic screening and advanced cancer definition on the percentage of advanced-stage cancers in a steady-state breast screening programme in the Netherlands.
    Br J Cancer. 2020;123:1191-1197.
    PubMed     Abstract available
    
    
    
37. AMBROISE G, Yu TT, Zhang B, Kacal M, et al
    Systematic analysis reveals a functional role for STAMBPL1 in the epithelial-mesenchymal transition process across multiple carcinomas.
    Br J Cancer. 2020;123:1164-1177.
    PubMed     Abstract available
    
    
    August 2020
38. BASHOUR SI, Ibrahim NK, Schomer DF, Hess KR, et al
    Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype.
    Br J Cancer. 2020 Aug 4. pii: 10.1038/s41416-020-1008.
    PubMed     Abstract available
    
    
    
39. MILLS MN, Ahmed KA
    Miliary breast cancer brain metastasis: a rare and aggressive form of central nervous system metastasis.
    Br J Cancer. 2020 Aug 4. pii: 10.1038/s41416-020-1001.
    PubMed     Abstract available
    
    
    July 2020
40. WALSH N, Andrieu C, O'Donovan P, Quinn C, et al
    Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer.
    Br J Cancer. 2020 Jul 27. pii: 10.1038/s41416-020-0999.
    PubMed     Abstract available
    
    
    
41. POON IK, Tsang JY, Li J, Chan SK, et al
    The significance of highlighting the oestrogen receptor low category in breast cancer.
    Br J Cancer. 2020 Jul 27. pii: 10.1038/s41416-020-1009.
    PubMed     Abstract available
    
    
    
42. SIMON J, Chaix M, Billa O, Kamga AM, et al
    Survival in patients with HR+/HER2- metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study.
    Br J Cancer. 2020 Jul 17. pii: 10.1038/s41416-020-0979.
    PubMed     Abstract available
    
    
    
43. BRUNELLE CL, Taghian AG
    Lymphoedema screening: setting the standard.
    Br J Cancer. 2020;123:1-2.
    PubMed     Abstract available
    
    
    
44. METCALFE KA, Price MA, Mansfield C, Hallett DC, et al
    Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
    Br J Cancer. 2020;123:268-274.
    PubMed     Abstract available
    
    
    
45. MCCARTNEY A, Malorni L
    Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors.
    Br J Cancer. 2020;123:176-177.
    PubMed     Abstract available
    
    
    
46. BUNDRED N, Foden P, Todd C, Morris J, et al
    Increases in arm volume predict lymphoedema and quality of life deficits after axillary surgery: a prospective cohort study.
    Br J Cancer. 2020;123:17-25.
    PubMed     Abstract available
    
    
    June 2020
47. PARK SA, Sung NJ, Choi BJ, Kim W, et al
    Gremlin-1 augments the oestrogen-related receptor alpha signalling through EGFR activation: implications for the progression of breast cancer.
    Br J Cancer. 2020 Jun 23. pii: 10.1038/s41416-020-0945.
    PubMed     Abstract available
    
    
    
48. MING C, Viassolo V, Probst-Hensch N, Dinov ID, et al
    Machine learning-based lifetime breast cancer risk reclassification compared with the BOADICEA model: impact on screening recommendations.
    Br J Cancer. 2020 Jun 22. pii: 10.1038/s41416-020-0937.
    PubMed     Abstract available
    
    
    
49. MESA-EGUIAGARAY I, Wild SH, Rosenberg PS, Bird SM, et al
    Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data.
    Br J Cancer. 2020 Jun 19. pii: 10.1038/s41416-020-0938.
    PubMed     Abstract available
    
    
    
50. ROBERTO A, Colombo C, Candiani G, Satolli R, et al
    A dynamic web-based decision aid to improve informed choice in organised breast cancer screening. A pragmatic randomised trial in Italy.
    Br J Cancer. 2020 Jun 17. pii: 10.1038/s41416-020-0935.
    PubMed     Abstract available
    
    
    
51. YUAN WH, Hsu HC, Chen YY, Wu CH, et al
    Supplemental breast cancer-screening ultrasonography in women with dense breasts: a systematic review and meta-analysis.
    Br J Cancer. 2020 Jun 12. pii: 10.1038/s41416-020-0928.
    PubMed     Abstract available
    
    
    
52. WAN G, Zhu J, Gu X, Yang Y, et al
    Human Schlafen 5 regulates reversible epithelial and mesenchymal transitions in breast cancer by suppression of ZEB1 transcription.
    Br J Cancer. 2020 Jun 3. pii: 10.1038/s41416-020-0873.
    PubMed     Abstract available
    
    
    
53. KOUTRAS A, Zagouri F, Koliou GA, Psoma E, et al
    Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial.
    Br J Cancer. 2020 Jun 3. pii: 10.1038/s41416-020-0909.
    PubMed     Abstract available
    
    
    
54. SUGANO T, Yoshida M, Masuda M, Ono M, et al
    Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma.
    Br J Cancer. 2020;122:1811-1817.
    PubMed     Abstract available
    
    
    May 2020
55. TANG M, Schaffer A, Kiely BE, Daniels B, et al
    Correction: Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016).
    Br J Cancer. 2020 May 29. pii: 10.1038/s41416-020-0908.
    PubMed     Abstract available
    
    
    
56. CHEUNG SM, Husain E, Masannat Y, Miller ID, et al
    Lactate concentration in breast cancer using advanced magnetic resonance spectroscopy.
    Br J Cancer. 2020 May 19. pii: 10.1038/s41416-020-0886.
    PubMed     Abstract available
    
    
    
57. ORLANDELLA FM, Mariniello RM, Mirabelli P, De Stefano AE, et al
    miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of breast cancer cells through targeting NUAK1 kinase.
    Br J Cancer. 2020 May 18. pii: 10.1038/s41416-020-0884.
    PubMed     Abstract available
    
    
    
58. LAMEIJER JRC, Voogd AC, Pijnappel RM, Setz-Pels W, et al
    Delayed breast cancer diagnosis after repeated recall at biennial screening mammography: an observational follow-up study from the Netherlands.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0870.
    PubMed     Abstract available
    
    
    
59. EGGEMANN H, Brucker C, Schrauder M, Thill M, et al
    Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis.
    Br J Cancer. 2020 May 5. pii: 10.1038/s41416-020-0857.
    PubMed     Abstract available
    
    
    
60. TOSS MS, Abidi A, Lesche D, Joseph C, et al
    The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
    Br J Cancer. 2020;122:1496-1506.
    PubMed     Abstract available
    
    
    April 2020
61. JAHN SW, Bosl A, Tsybrovskyy O, Gruber-Rossipal C, et al
    Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0838.
    PubMed     Abstract available
    
    
    
62. MUKAI H, Yamaguchi T, Takahashi M, Hozumi Y, et al
    Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study.
    Br J Cancer. 2020 Apr 2. pii: 10.1038/s41416-020-0815.
    PubMed     Abstract available
    
    
    March 2020
63. BLONDEAUX E, Lambertini M, Michelotti A, Conte B, et al
    Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study.
    Br J Cancer. 2020 Mar 31. pii: 10.1038/s41416-020-0816.
    PubMed     Abstract available
    
    
    
64. MCKENZIE HS, Maishman T, Simmonds P, Durcan L, et al
    Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients.
    Br J Cancer. 2020 Mar 31. pii: 10.1038/s41416-020-0784.
    PubMed     Abstract available
    
    
    
65. RENEHAN AG, Pegington M, Harvie MN, Sperrin M, et al
    Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom).
    Br J Cancer. 2020 Mar 23. pii: 10.1038/s41416-020-0807.
    PubMed     Abstract available
    
    
    
66. EIGER D, Ponde NF, Agbor-Tarh D, Moreno-Aspitia A, et al
    Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.
    Br J Cancer. 2020 Mar 16. pii: 10.1038/s41416-020-0786.
    PubMed     Abstract available
    
    
    February 2020
67. WONG EM, Southey MC, Terry MB
    Integrating DNA methylation measures to improve clinical risk assessment: are we there yet? The case of BRCA1 methylation marks to improve clinical risk assessment of breast cancer.
    Br J Cancer. 2020 Feb 18. pii: 10.1038/s41416-019-0720.
    PubMed     Abstract available
    
    
    
68. BENS A, Dehlendorff C, Friis S, Cronin-Fenton D, et al
    The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study.
    Br J Cancer. 2020 Feb 17. pii: 10.1038/s41416-020-0747.
    PubMed     Abstract available
    
    
    
69. VARIKUTI S, Singh B, Volpedo G, Ahirwar DK, et al
    Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells.
    Br J Cancer. 2020 Feb 6. pii: 10.1038/s41416-020-0743.
    PubMed     Abstract available
    
    
    
70. ROBERTS C, Strauss VY, Kopijasz S, Gourley C, et al
    Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
    Br J Cancer. 2020;122:483-490.
    PubMed     Abstract available
    
    
    
71. VISSIO E, Metovic J, Osella-Abate S, Bertero L, et al
    Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling.
    Br J Cancer. 2020;122:382-387.
    PubMed     Abstract available
    
    
    
72. EVANS DG, Edwards M, Duffy SW, Tischkowitz M, et al
    Sporadic implementation of UK familial mammographic surveillance guidelines 15 years after original publication.
    Br J Cancer. 2020;122:329-332.
    PubMed     Abstract available
    
    
    January 2020
73. LEREBOURS F, Pulido M, Fourme E, Debled M, et al
    Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.
    Br J Cancer. 2020 Jan 31. pii: 10.1038/s41416-020-0733.
    PubMed     Abstract available
    
    
    
74. FARHAT D, Leon S, Ghayad SE, Gadot N, et al
    Lipoic acid decreases breast cancer cell proliferation by inhibiting IGF-1R via furin downregulation.
    Br J Cancer. 2020 Jan 28. pii: 10.1038/s41416-020-0729.
    PubMed     Abstract available
    
    
    
75. CASCIANO JC, Perry C, Cohen-Nowak AJ, Miller KD, et al
    MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer.
    Br J Cancer. 2020 Jan 16. pii: 10.1038/s41416-019-0711.
    PubMed     Abstract available
    
    
    
76. MULL BB, Livingston JA, Patel N, Bui T, et al
    Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer.
    Br J Cancer. 2020 Jan 16. pii: 10.1038/s41416-019-0707.
    PubMed     Abstract available
    
    
    
77. RIBI K, Luo W, Colleoni M, Karlsson P, et al
    Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
    Br J Cancer. 2020 Jan 16. pii: 10.1038/s41416-019-0709.
    PubMed     Abstract available
    
    
    
78. HARVIE M, Pegington M, Bundred N, Campbell A, et al
    Reply to Comment on "The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial".
    Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0715.
    PubMed    
    
    
    
79. BAIL JR, Halilova KI, Demark-Wahnefried W, Reeves MM, et al
    Comment on "The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial".
    Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0714.
    PubMed    
    
    
    
80. AHN S, Kim HJ, Kang E, Kim EK, et al
    Genomic profiling of multiple breast cancer reveals inter-lesional heterogeneity.
    Br J Cancer. 2020 Jan 13. pii: 10.1038/s41416-019-0713.
    PubMed     Abstract available
    
    
    
81. GUO W, Fensom GK, Reeves GK, Key TJ, et al
    Physical activity and breast cancer risk: results from the UK Biobank prospective cohort.
    Br J Cancer. 2020 Jan 10. pii: 10.1038/s41416-019-0700.
    PubMed     Abstract available
    
    
    
82. CICCARONE F, Di Leo L, Lazzarino G, Maulucci G, et al
    Aconitase 2 inhibits the proliferation of MCF-7 cells promoting mitochondrial oxidative metabolism and ROS/FoxO1-mediated autophagic response.
    Br J Cancer. 2020;122:182-193.
    PubMed     Abstract available
    
    
    December 2019
83. HUNTER FW, Barker HR, Lipert B, Rothe F, et al
    Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.
    Br J Cancer. 2019 Dec 16. pii: 10.1038/s41416-019-0635.
    PubMed     Abstract available
    
    
    
84. LORD SR, Collins JM, Cheng WC, Haider S, et al
    Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin.
    Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0665.
    PubMed     Abstract available
    
    
    
85. KAWASHIMA M, Tokiwa M, Nishimura T, Kawata Y, et al
    High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer.
    Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0662.
    PubMed     Abstract available
    
    
    
86. SOLA-PENNA M, Paixao LP, Branco JR, Ochioni AC, et al
    Serotonin activates glycolysis and mitochondria biogenesis in human breast cancer cells through activation of the Jak1/STAT3/ERK1/2 and adenylate cyclase/PKA, respectively.
    Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0640.
    PubMed     Abstract available
    
    
    
87. ANSARI RE, Craze ML, Althobiti M, Alfarsi L, et al
    Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer.
    Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0626.
    PubMed     Abstract available
    
    
    
88. HO-PUN-CHEUNG A, Bazin H, Boissiere-Michot F, Mollevi C, et al
    Quantification of HER1, HER2 and HER3 by time-resolved Forster resonance energy transfer in FFPE triple-negative breast cancer samples.
    Br J Cancer. 2019 Dec 3. pii: 10.1038/s41416-019-0670.
    PubMed     Abstract available
    
    
    November 2019
89. NICOUD MB, Sterle HA, Massari NA, Taquez Delgado MA, et al
    Study of the antitumour effects and the modulation of immune response by histamine in breast cancer.
    Br J Cancer. 2019 Nov 21. pii: 10.1038/s41416-019-0636.
    PubMed     Abstract available
    
    
    
90. WITZEL I, Loibl S, Wirtz R, Fasching PA, et al
    Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial.
    Br J Cancer. 2019 Nov 15. pii: 10.1038/s41416-019-0630.
    PubMed     Abstract available
    
    
    
91. DARLIX A, Louvel G, Fraisse J, Jacot W, et al
    Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.
    Br J Cancer. 2019 Nov 13. pii: 10.1038/s41416-019-0619.
    PubMed     Abstract available
    
    
    
92. XUE Y, Lian W, Zhi J, Yang W, et al
    HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer.
    Br J Cancer. 2019 Nov 6. pii: 10.1038/s41416-019-0625.
    PubMed     Abstract available
    
    
    
93. SIM SH, Park IH, Jung KH, Kim SB, et al
    Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16).
    Br J Cancer. 2019 Nov 6. pii: 10.1038/s41416-019-0618.
    PubMed     Abstract available
    
    
    
94. TANG M, Schaffer A, Kiely BE, Daniels B, et al
    Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016).
    Br J Cancer. 2019 Nov 1. pii: 10.1038/s41416-019-0612.
    PubMed     Abstract available
    
    
    September 2019
95. JOSEPH C, Al-Izzi S, Alsaleem M, Kurozumi S, et al
    Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.
    Br J Cancer. 2019 Sep 27. pii: 10.1038/s41416-019-0589.
    PubMed     Abstract available
    
    
    
96. MUNZONE E, Pagan E, Bagnardi V, Mazzocco K, et al
    Reply to Comments on: "Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp cooling system in early breast cancer patients treated with anthracyclines."
    Br J Cancer. 2019 Sep 17. pii: 10.1038/s41416-019-0577.
    PubMed    
    
    
    
97. KAKO J, Kajiwara K, Kobayashi M, Oosono Y, et al
    Comment on: "Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines".
    Br J Cancer. 2019 Sep 17. pii: 10.1038/s41416-019-0576.
    PubMed    
    
    
    
98. SAFI N, Anazodo A, Dickinson JE, Lui K, et al
    In utero exposure to breast cancer treatment: a population-based perinatal outcome study.
    Br J Cancer. 2019 Sep 6. pii: 10.1038/s41416-019-0563.
    PubMed     Abstract available
    
    
    
99. JONES ME, Schoemaker MJ, McFadden EC, Wright LB, et al
    Reply to Comment on: "Night shift work and risk of breast cancer in women: the Generations Study cohort".
    Br J Cancer. 2019 Sep 5. pii: 10.1038/s41416-019-0568.
    PubMed    
    
    
    
100. KOGEVINAS M
     Comment on: "Night shift work and risk of breast cancer in women: the Generations Study cohort".
     Br J Cancer. 2019 Sep 5. pii: 10.1038/s41416-019-0567.
     PubMed    
     
     
     
101. CHATTERJEE A, Jana S, Chatterjee S, Wastall LM, et al
     MicroRNA-222 reprogrammed cancer-associated fibroblasts enhance growth and metastasis of breast cancer.
     Br J Cancer. 2019 Sep 4. pii: 10.1038/s41416-019-0566.
     PubMed     Abstract available
     
     
     August 2019
102. BHATTARAI S, Klimov S, Aleskandarany MA, Burrell H, et al
     Machine learning-based prediction of breast cancer growth rate in vivo.
     Br J Cancer. 2019 Aug 9. pii: 10.1038/s41416-019-0539.
     PubMed     Abstract available
     
     
     
103. HARVIE M, Pegington M, McMullan D, Bundred N, et al
     The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial.
     Br J Cancer. 2019 Aug 1. pii: 10.1038/s41416-019-0522.
     PubMed     Abstract available
     
     
     July 2019
104. MUNZONE E, Bagnardi V, Campenni G, Mazzocco K, et al
     Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines.
     Br J Cancer. 2019 Jul 15. pii: 10.1038/s41416-019-0520.
     PubMed     Abstract available
     
     
     
105. LEE DW, Ryu HS, Jin MS, Lee KH, et al
     Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients.
     Br J Cancer. 2019 Jul 11. pii: 10.1038/s41416-019-0511.
     PubMed     Abstract available
     
     
     June 2019
106. CAPULLI M, Hristova D, Valbret Z, Carys K, et al
     Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry.
     Br J Cancer. 2019 Jun 26. pii: 10.1038/s41416-019-0501.
     PubMed     Abstract available
     
     
     May 2019
107. JONES ME, Schoemaker MJ, McFadden EC, Wright LB, et al
     Night shift work and risk of breast cancer in women: the Generations Study cohort.
     Br J Cancer. 2019 May 29. pii: 10.1038/s41416-019-0485.
     PubMed     Abstract available
     
     
     
108. KUROZUMI S, Joseph C, Sonbul S, Alsaeed S, et al
     A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.
     Br J Cancer. 2019 May 22. pii: 10.1038/s41416-019-0486.
     PubMed     Abstract available
     
     
     
109. LOURO J, Posso M, Hilton Boon M, Roman M, et al
     A systematic review and quality assessment of individualised breast cancer risk prediction models.
     Br J Cancer. 2019 May 22. pii: 10.1038/s41416-019-0476.
     PubMed     Abstract available
     
     
     
110. LIM B, Murthy RK, Lee J, Jackson SA, et al
     A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
     Br J Cancer. 2019 May 17. pii: 10.1038/s41416-019-0473.
     PubMed     Abstract available
     
     
     April 2019
111. DAULAT AM, Finetti P, Revinski D, Silveira Wagner M, et al
     ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer.
     Br J Cancer. 2019 Apr 11. pii: 10.1038/s41416-019-0448.
     PubMed     Abstract available
     
     
     
112. RIBI K, Luo W, Colleoni M, Karlsson P, et al
     Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
     Br J Cancer. 2019 Apr 10. pii: 10.1038/s41416-019-0435.
     PubMed     Abstract available
     
     
     February 2019
113. ABDEL-FATAH TMA, Broom RJ, Lu J, Moseley PM, et al
     SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.
     Br J Cancer. 2019 Feb 28. pii: 10.1038/s41416-019-0405.
     PubMed     Abstract available
     
     
     
114. LI N, Kong J, Lin Z, Yang Y, et al
     Ezrin promotes breast cancer progression by modulating AKT signals.
     Br J Cancer. 2019 Feb 26. pii: 10.1038/s41416-019-0383.
     PubMed     Abstract available
     
     
     
115. MEJDAHL MK, Wohlfahrt J, Holm M, Balslev E, et al
     Breast cancer mortality in synchronous bilateral breast cancer patients.
     Br J Cancer. 2019 Feb 26. pii: 10.1038/s41416-019-0403.
     PubMed     Abstract available
     
     
     
116. ESCALA-GARCIA M, Guo Q, Dork T, Canisius S, et al
     Genome-wide association study of germline variants and breast cancer-specific mortality.
     Br J Cancer. 2019 Feb 21. pii: 10.1038/s41416-019-0393.
     PubMed     Abstract available
     
     
     
117. MILEVSKIY MJG, Gujral U, Del Lama Marques C, Stone A, et al
     MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer.
     Br J Cancer. 2019 Feb 20. pii: 10.1038/s41416-019-0395.
     PubMed     Abstract available
     
     
     
118. FUJIWARA Y, Mukai H, Saeki T, Ro J, et al
     A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
     Br J Cancer. 2019 Feb 12. pii: 10.1038/s41416-019-0391.
     PubMed     Abstract available
     
     
     
119. METCALFE K, Lynch HT, Foulkes WD, Tung N, et al
     Oestrogen receptor status and survival in women with BRCA2-associated breast cancer.
     Br J Cancer. 2019 Feb 6. pii: 10.1038/s41416-019-0376.
     PubMed     Abstract available
     
     
     January 2019
120. OWEN LJ, Monaghan PJ, Armstrong A, Keevil BG, et al
     Oestradiol measurement during fulvestrant treatment for breast cancer.
     Br J Cancer. 2019 Jan 25. pii: 10.1038/s41416-019-0378.
     PubMed     Abstract available
     
     
     
121. LEE CK, Scott C, Lindeman GJ, Hamilton A, et al
     Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
     Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0349.
     PubMed     Abstract available
     
     
     
122. EGGEMANN H, Bernreiter AL, Reinisch M, Loibl S, et al
     Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis.
     Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0369.
     PubMed     Abstract available
     
     
     December 2018
123. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
     Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
     Br J Cancer. 2018 Dec 25. pii: 10.1038/s41416-018-0344.
     PubMed    
     
     
     
124. KYBA CCM, Spitschan M
     Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105000 UK women in the Generations Study'.
     Br J Cancer. 2018 Dec 25. pii: 10.1038/s41416-018-0203.
     PubMed    
     
     
     
125. PEGRAM MD, Bondarenko I, Zorzetto MMC, Hingmire S, et al
     PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
     Br J Cancer. 2018 Dec 20. pii: 10.1038/s41416-018-0340.
     PubMed     Abstract available
     
     
     
126. ROMAN M, Hofvind S, von Euler-Chelpin M, Castells X, et al
     Long-term risk of screen-detected and interval breast cancer after false-positive results at mammography screening: joint analysis of three national cohorts.
     Br J Cancer. 2018 Dec 19. pii: 10.1038/s41416-018-0358.
     PubMed     Abstract available
     
     
     
127. LOPEZ-KNOWLES E, Pearson A, Schuster G, Gellert P, et al
     Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
     Br J Cancer. 2018 Dec 19. pii: 10.1038/s41416-018-0345.
     PubMed     Abstract available
     
     
     November 2018
128. TIAN J, Raffa FA, Dai M, Moamer A, et al
     Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
     Br J Cancer. 2018 Nov 28. pii: 10.1038/s41416-018-0287.
     PubMed     Abstract available
     
     
     
129. GIANNAKEAS V, Cadarette SM, Ban JK, Lipscombe L, et al
     Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study.
     Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0225.
     PubMed     Abstract available
     
     
     
130. SNELL CE, Gough M, Liu C, Middleton K, et al
     Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-alpha and progesterone receptor-b.
     Br J Cancer. 2018 Nov 9. pii: 10.1038/s41416-018-0331.
     PubMed     Abstract available
     
     
     October 2018
131. MCGREGOR RJ, Chau YY, Kendall TJ, Artibani M, et al
     WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer.
     Br J Cancer. 2018 Oct 30. pii: 10.1038/s41416-018-0317.
     PubMed     Abstract available
     
     
     
132. MUNSTER P, Krop IE, LoRusso P, Ma C, et al
     Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
     Br J Cancer. 2018 Oct 26. pii: 10.1038/s41416-018-0235.
     PubMed     Abstract available
     
     
     
133. TAMBOUR M, Holt M, Speyer A, Christensen R, et al
     Manual lymphatic drainage adds no further volume reduction to Complete Decongestive Therapy on breast cancer-related lymphoedema: a multicentre, randomised, single-blind trial.
     Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0306.
     PubMed     Abstract available
     
     
     
134. BERTUCCI F, Finetti P, Simeone I, Hendrickx W, et al
     The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.
     Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0309.
     PubMed     Abstract available
     
     
     
135. LANGBALLE R, Cronin-Fenton D, Dehlendorff C, Jensen MB, et al
     Statin use and risk of contralateral breast cancer: a nationwide cohort study.
     Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0252.
     PubMed     Abstract available
     
     
     
136. WALASZEK K, Lower EE, Ziolkowski P, Weber GF, et al
     Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis.
     Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0228.
     PubMed     Abstract available
     
     
     
137. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
     Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
     Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0177.
     PubMed    
     
     
     
138. SCIMECA M, Urbano N, Bonfiglio R, Schillaci O, et al
     Breast osteoblast-like cells: a new biomarker for the management of breast cancer.
     Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0255.
     PubMed     Abstract available
     
     
     
139. MEURS CJC, van Rosmalen J, Menke-Pluijmers MBE, Ter Braak BPM, et al
     A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers.
     Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0276.
     PubMed     Abstract available
     
     
     
140. CHAKRABORTY S, Jiang C, Gau D, Oddo M, et al
     Profilin-1 deficiency leads to SMAD3 upregulation and impaired 3D outgrowth of breast cancer cells.
     Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0284.
     PubMed     Abstract available
     
     
     
141. O'CARRIGAN B, Lim JSJ, Jalil A, Harris SJ, et al
     Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.
     Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0290.
     PubMed     Abstract available
     
     
     
142. BAJOR M, Zych AO, Graczyk-Jarzynka A, Muchowicz A, et al
     Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents.
     Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0263.
     PubMed     Abstract available
     
     
     
143. KRUGER DT, Beelen KJ, Opdam M, Sanders J, et al
     Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.
     Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0221.
     PubMed     Abstract available
     
     
     
144. STEVENS RG
     Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study'.
     Br J Cancer. 2018 Oct 3. pii: 10.1038/s41416-018-0058.
     PubMed    
     
     
     
145. BECKWITT CH, Clark AM, Ma B, Whaley D, et al
     Statins attenuate outgrowth of breast cancer metastases.
     Br J Cancer. 2018;119:1094-1105.
     PubMed     Abstract available
     
     
     
146. MADSSEN TS, Thune I, Flote VG, Lundgren S, et al
     Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment.
     Br J Cancer. 2018;119:1144-1154.
     PubMed     Abstract available
     
     
     September 2018
147. GRAY E, Marti J, Brewster DH, Wyatt JC, et al
     Independent validation of the PREDICT breast cancer prognosis prediction tool in 45,789 patients using Scottish Cancer Registry data.
     Br J Cancer. 2018 Sep 17. pii: 10.1038/s41416-018-0256.
     PubMed     Abstract available
     
     
     August 2018
148. BOEKEL NB, Jacobse JN, Schaapveld M, Hooning MJ, et al
     Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer.
     Br J Cancer. 2018 Aug 1. pii: 10.1038/s41416-018-0159.
     PubMed     Abstract available
     
     
     July 2018
149. SAHA A, Harowicz MR, Grimm LJ, Kim CE, et al
     A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features.
     Br J Cancer. 2018 Jul 23. pii: 10.1038/s41416-018-0185.
     PubMed     Abstract available
     
     
     
150. TAKADA K, Kashiwagi S, Goto W, Asano Y, et al
     Significance of re-biopsy for recurrent breast cancer in the immune tumour microenvironment.
     Br J Cancer. 2018 Jul 23. pii: 10.1038/s41416-018-0197.
     PubMed     Abstract available
     
     
     
151. LAMMERS PE, Dank M, Masetti R, Abbas R, et al
     Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer.
     Br J Cancer. 2018 Jul 13. pii: 10.1038/s41416-018-0147.
     PubMed     Abstract available
     
     
     
152. STERLE HA, Nicoud MB, Massari NA, Taquez Delgado MA, et al
     Immunomodulatory role of histamine H4 receptor in breast cancer.
     Br J Cancer. 2018 Jul 10. pii: 10.1038/s41416-018-0173.
     PubMed     Abstract available
     
     
     June 2018
153. LO LL, Milne RL, Liao Y, Cuzick J, et al
     Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ.
     Br J Cancer. 2018 Jun 21. pii: 10.1038/s41416-018-0120.
     PubMed     Abstract available
     
     
     
154. CHERIYATH V, Kaur J, Davenport A, Khalel A, et al
     G1P3 (IFI6), a mitochondrial localised antiapoptotic protein, promotes metastatic potential of breast cancer cells through mtROS.
     Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0137.
     PubMed     Abstract available
     
     
     
155. GUIU S, Mollevi C, Charon-Barra C, Boissiere F, et al
     Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
     Br J Cancer. 2018 Jun 8. pii: 10.1038/s41416-018-0142.
     PubMed     Abstract available
     
     
     
156. DERKS MGM, Bastiaannet E, Kiderlen M, Hilling DE, et al
     Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group.
     Br J Cancer. 2018 Jun 7. pii: 10.1038/s41416-018-0090.
     PubMed     Abstract available
     
     
     
157. ROHAN TE, Miller CA, Li T, Wang Y, et al
     Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer.
     Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0089.
     PubMed     Abstract available
     
     
     
158. TUNG NM, Garber JE
     BRCA1/2 testing: therapeutic implications for breast cancer management.
     Br J Cancer. 2018 Jun 5. pii: 10.1038/s41416-018-0127.
     PubMed     Abstract available
     
     
     
159. HALKETT G, O'Connor M, Jefford M, Aranda S, et al
     RT Prepare: a radiation therapist-delivered intervention reduces psychological distress in women with breast cancer referred for radiotherapy.
     Br J Cancer. 2018 Jun 1. pii: 10.1038/s41416-018-0112.
     PubMed     Abstract available
     
     
     May 2018
160. WEIN L, Luen SJ, Savas P, Salgado R, et al
     Checkpoint blockade in the treatment of breast cancer: current status and future directions.
     Br J Cancer. 2018 May 29. pii: 10.1038/s41416-018-0126.
     PubMed     Abstract available
     
     
     
161. GULLO G, Walsh N, Fennelly D, Bose R, et al
     Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
     Br J Cancer. 2018 May 18. pii: 10.1038/s41416-018-0114.
     PubMed     Abstract available
     
     
     
162. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
     Reply to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
     Br J Cancer. 2018 May 17. pii: 10.1038/s41416-018-0092.
     PubMed    
     
     
     
163. MORTAZAVI SMJ
     Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study'.
     Br J Cancer. 2018 May 17. pii: 10.1038/s41416-018-0060.
     PubMed    
     
     
     
164. FRENCH DP, Southworth J, Howell A, Harvie M, et al
     Psychological impact of providing women with personalised 10-year breast cancer risk estimates.
     Br J Cancer. 2018 May 8. pii: 10.1038/s41416-018-0069.
     PubMed     Abstract available
     
     
     
165. CHEN S, Wang H, Li Z, You J, et al
     Interaction of WBP2 with ERalpha increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription.
     Br J Cancer. 2018 May 1. pii: 10.1038/s41416-018-0119.
     PubMed     Abstract available
     
     
     
166. DERKS-SMEETS IAP, Schrijver LH, de Die-Smulders CEM, Tjan-Heijnen VCG, et al
     Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers.
     Br J Cancer. 2018 May 1. pii: 10.1038/s41416-018-0139.
     PubMed     Abstract available
     
     
     April 2018
167. BHARTI R, Dey G, Das AK, Mandal M, et al
     Differential expression of IL-6/IL-6R and MAO-A regulates invasion/angiogenesis in breast cancer.
     Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0078.
     PubMed     Abstract available
     
     
     
168. ORECCHIONI S, Talarico G, Labanca V, Calleri A, et al
     Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
     Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0076.
     PubMed     Abstract available
     
     
     
169. LIIKANEN JS, Leidenius MH, Joensuu H, Vironen JH, et al
     Prognostic value of isolated tumour cells in sentinel lymph nodes in early-stage breast cancer: a prospective study.
     Br J Cancer. 2018 Apr 24. pii: 10.1038/s41416-018-0052.
     PubMed     Abstract available
     
     
     March 2018
170. JOSEPH C, Macnamara O, Craze M, Russell R, et al
     Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
     Br J Cancer. 2018 Mar 28. pii: 10.1038/s41416-018-0041.
     PubMed     Abstract available
     
     
     
171. QUIROS-GONZALEZ I, Tomaszewski MR, Aitken SJ, Ansel-Bollepalli L, et al
     Optoacoustics delineates murine breast cancer models displaying angiogenesis and vascular mimicry.
     Br J Cancer. 2018 Mar 26. pii: 10.1038/s41416-018-0033.
     PubMed     Abstract available
     
     
     
172. MCNAMARA KM, Guestini F, Sauer T, Touma J, et al
     In breast cancer subtypes steroid sulfatase (STS) is associated with less aggressive tumour characteristics.
     Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0034.
     PubMed     Abstract available
     
     
     
173. GYORFFY B, Pongor L, Bottai G, Li X, et al
     An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.
     Br J Cancer. 2018 Mar 21. pii: 10.1038/s41416-018-0030.
     PubMed     Abstract available
     
     
     
174. EL ANSARI R, Craze ML, Diez-Rodriguez M, Nolan CC, et al
     The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
     Br J Cancer. 2018 Mar 16. pii: 10.1038/s41416-018-0038.
     PubMed     Abstract available
     
     
     
175. SAUERBREI W, Haeussler T
     Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses'.
     Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0023.
     PubMed    
     
     
     
176. POUJADE FA, Mannion A, Brittain N, Theodosi A, et al
     WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer.
     Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0056.
     PubMed     Abstract available
     
     
     
177. PAPADAKIS ES, Reeves T, Robson NH, Maishman T, et al
     Reply to 'Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses''.
     Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0032.
     PubMed    
     
     
     February 2018
178. REMSIK J, Fedr R, Navratil J, Bino L, et al
     Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer.
     Br J Cancer. 2018 Feb 20. pii: bjc2017497. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
179. DOSS M
     Comment on '30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure'.
     Br J Cancer. 2018 Feb 13. pii: bjc2017481. doi: 10.1038/bjc.2017.
     PubMed    
     
     
     
180. HSIEH WH, Lin IF, Ho JC, Chang PW, et al
     Reply to 'Comment on '30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure''.
     Br J Cancer. 2018 Feb 13. pii: bjc2017490. doi: 10.1038/bjc.2017.
     PubMed    
     
     
     January 2018
181. LEGLER K, Rosprim R, Karius T, Eylmann K, et al
     Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer.
     Br J Cancer. 2018 Jan 30. pii: bjc2017472. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
182. FOUKAKIS T, Lovrot J, Matikas A, Zerdes I, et al
     Immune gene expression and response to chemotherapy in advanced breast cancer.
     Br J Cancer. 2018 Jan 25. pii: bjc2017446. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
183. PLYM A, Bower H, Fredriksson I, Holmberg L, et al
     Loss in working years after a breast cancer diagnosis.
     Br J Cancer. 2018 Jan 23. pii: bjc2017456. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
184. GOEDERT JJ, Hua X, Bielecka A, Okayasu I, et al
     Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota.
     Br J Cancer. 2018 Jan 23. pii: bjc2017435. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
185. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
     Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study.
     Br J Cancer. 2018 Jan 23. pii: bjc2017359. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
186. TRUDEL-FITZGERALD C, Zhou ES, Poole EM, Zhang X, et al
     Sleep and survival among women with breast cancer: 30 years of follow-up within the Nurses' Health Study.
     Br J Cancer. 2018 Jan 9. pii: bjc2017437. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     December 2017
187. REDDY SM, Barcenas CH, Sinha AK, Hsu L, et al
     Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.
     Br J Cancer. 2017 Dec 12. pii: bjc2017379. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     November 2017
188. CRAZE ML, Cheung H, Jewa N, Coimbra NDM, et al
     MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
     Br J Cancer. 2017 Nov 23. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
189. NANDY SB, Orozco A, Lopez-Valdez R, Roberts R, et al
     Glucose insult elicits hyperactivation of cancer stem cells through miR-424-cdc42-prdm14 signalling axis.
     Br J Cancer. 2017;117:1665-1675.
     PubMed     Abstract available
     
     
     
190. DANIELS B, Kiely BE, Houssami N, Lord SJ, et al
     Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).
     Br J Cancer. 2017 Nov 14. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     October 2017
191. O'SULLIVAN D, Dowling P, Joyce H, McAuley E, et al
     A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.
     Br J Cancer. 2017;117:1326-1335.
     PubMed     Abstract available
     
     
     
192. HSIEH WH, Lin IF, Ho JC, Chang PW, et al
     30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure.
     Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     September 2017
193. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
     Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
     Br J Cancer. 2017;117:1048-1062.
     PubMed     Abstract available
     
     
     
194. PONZETTI M, Capulli M, Angelucci A, Ventura L, et al
     Non-conventional role of haemoglobin beta in breast malignancy.
     Br J Cancer. 2017;117:994-1006.
     PubMed     Abstract available
     
     
     
195. MORRELL S, Roder D, Taylor R
     Reply to 'Comment on 'Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study''.
     Br J Cancer. 2017 Sep 21. doi: 10.1038/bjc.2017.
     PubMed    
     
     
     
196. GREGOIRE C, Bragard I, Jerusalem G, Etienne AM, et al
     Group interventions to reduce emotional distress and fatigue in breast cancer patients: a 9-month follow-up pragmatic trial.
     Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
197. YE ZJ, Qiu HZ, Liang MZ, Liu ML, et al
     Effect of a mentor-based, supportive-expressive program, Be Resilient to Breast Cancer, on survival in metastatic breast cancer: a randomised, controlled intervention trial.
     Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
198. OSAKO T, Iwase T, Ushijima M, Yonekura R, et al
     A new molecular-based lymph node staging classification determines the prognosis of breast cancer patients.
     Br J Cancer. 2017 Sep 14. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
199. KLIMOV S, Rida PC, Aleskandarany MA, Green AR, et al
     Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
     Br J Cancer. 2017;117:826-834.
     PubMed     Abstract available
     
     
     August 2017
200. SHARMA R, Huang X, Brekken RA, Schroit AJ, et al
     Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies.
     Br J Cancer. 2017;117:545-552.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: